Ligand Pharmaceuticals, Inc. (LGND) Misses Q3 EPS by 21c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $279.44 +6.59%
EPS Growth %: +25.6%
Financial Fact:
Gain on sale of a product line: 0
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +25.6%
Financial Fact:
Gain on sale of a product line: 0
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q3 EPS of ($0.20), $0.21 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $5.7 million versus the consensus estimate of $5.9 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ligand prices $625M convertible notes due 2031 at 0% interest
- Worthington Industries (WOR) Misses Q4 EPS by 9c
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
